Thermo Fisher Scientific (NYSE:TMO) Posts Quarterly Earnings Results, Beats Expectations By $0.28 EPS

Thermo Fisher Scientific (NYSE:TMO) posted its quarterly earnings data on Wednesday. The medical research company reported $6.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.40 by $0.28, FiscalAI reports. The business had revenue of $12.14 billion for the quarter, compared to analysts’ expectations of $11.95 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.

Here are the key takeaways from Thermo Fisher Scientific’s conference call:

• Thermo Fisher raised its 2026 outlook, increasing revenue guidance to $47.7 billion–$48.2 billion, organic growth guidance to 4%, adjusted EPS guidance to $25.13–$25.43, and free cash flow guidance to $7.0 billion–$7.5 billion.
• Third-quarter performance exceeded expectations, with revenue up 9% to $12.14 billion, organic growth of 6%, adjusted EPS up 15% to $6.68, and adjusted operating margin expanding 120 basis points to 24.5%. Growth was led by Pharma Services, clinical research, electron microscopy, and improving biotech demand.
• Management reported continued strengthening in pharma and biotech customer activity, including low-to-mid/high-single-digit growth across key areas, improving biotech funding and confidence, and strong demand for clinical research, bioproduction, and semiconductor-related electron microscopy.
• The quarter benefited from approximately $60 million of net tariff-refund recovery, contributing $0.15 to adjusted EPS, although the company reinvested part of the proceeds in AI deployment, Pharma Services capacity, and employee investments. The refund benefit is largely one-time, while fourth-quarter organic growth guidance remains at 4% after some Pharma Services activity shifted into the third quarter.
• Thermo Fisher highlighted expanding AI capabilities across instruments and services, including AI-enabled cryo-electron microscopy workflows and a clinical research assistant, while the Clario acquisition and bioproduction investments are reportedly generating strong customer adoption and potential revenue synergies.

Thermo Fisher Scientific Stock Up 1.2%

Shares of TMO opened at $687.72 on Wednesday. Thermo Fisher Scientific has a fifty-two week low of $435.27 and a fifty-two week high of $704.00. The company’s fifty day moving average is $640.60 and its two-hundred day moving average is $551.25. The firm has a market cap of $254.28 billion, a PE ratio of 28.51, a price-to-earnings-growth ratio of 2.83 and a beta of 0.87. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74.

Insider Transactions at Thermo Fisher Scientific

In related news, VP Lisa Britt sold 11,440 shares of the stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $613.12, for a total value of $7,014,092.80. Following the transaction, the vice president directly owned 14,784 shares of the company’s stock, valued at approximately $9,064,366.08. This trade represents a 43.62% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Michael Shafer sold 25,500 shares of Thermo Fisher Scientific stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total value of $15,300,000.00. Following the completion of the transaction, the executive vice president owned 20,994 shares in the company, valued at $12,596,400. The trade was a 54.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 73,768 shares of company stock valued at $44,122,820. Corporate insiders own 0.33% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently commented on TMO shares. Jefferies Financial Group reiterated a “buy” rating and issued a $630.00 target price on shares of Thermo Fisher Scientific in a research note on Thursday, July 23rd. Guggenheim initiated coverage on Thermo Fisher Scientific in a report on Thursday, October 15th. They issued a “buy” rating for the company. BMO Capital Markets cut Thermo Fisher Scientific to a “market perform” rating in a report on Wednesday, September 9th. Citigroup downgraded shares of Thermo Fisher Scientific from a “buy” rating to an “underperform” rating in a research note on Wednesday, September 9th. Finally, Evercore set a $570.00 price objective on shares of Thermo Fisher Scientific in a report on Monday, July 6th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $654.05.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.

Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.